Inventiva
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50 Rue De Dijon, Daix, Bourgogne-Franche...Phone Number
+33 380447500Website
www.inventivapharma.comRevenue
<$5 MillionStock Symbol
IVAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcomes.Explore more
Inventiva Org Chart
PH
Chief People Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inventiva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Inventiva has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Inventiva has new funding data
Product Launch: Get notified when Inventiva launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Inventiva
Click to see if Inventiva had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Inventiva is spiking on competitors!
Earning: See what the market has to say on Inventiva recently announced quarterly report
Inventiva, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Inventiva as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Inventiva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inventiva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inventiva.
Inventiva financials insights
Gather financial insights about Inventiva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$16.4M
Stock Offering
$107.7M
2023
Share Placement
$36.7M
2024
Private Equity
$99.6M
2025
Debt
$131M
2026
Debt
$151.2M
Inventiva Tech Stack
A closer look at the technologies used by Inventiva
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Inventiva News & Media
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the press release remains unchanged. As aINVENTIVA | Globenewswire - Via Ritzau
Inventiva Announces Preliminary Financial Results for the First Half of 2026¹Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues.Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “Combined Transaction”) through the issuance of approximately 15.7
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inventiva
Sign Up For FreeTo access detailed company insights
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcom... Read More
